BrightPath Biotherapeutics: Materials for the Fiscal Year Ending March 2026 Earnings Presentation

JPXMay 24 19:30 ET · Announcements

BrightPath Biothera Sees Parent FY Loss Y1.95B

Dow JonesMay 14 02:34 ET

BrightPath Biothera FY Parent Loss Y1.30B Vs Loss Y1.15B

Dow JonesMay 14 02:34 ET

BrightPath Biotherapeutics: Financial Results Briefing for the Fiscal Year Ending March 2026 [Japanese GAAP] (Non-Consolidated)

JPXMay 14 02:32 ET · Announcements

Bright Path Applauds President's FY2027 Budget for Investing in Domestic Pharmaceutical Manufacturing

PR NewswireApr 14 08:30 ET

Morpho, Netyear, and others

Storage King (2997) acquired real estate for sale in Setagaya-ku and Ota-ku, Tokyo. Genepa (3195) obtained a license to manufacture and sell third-class medical devices. Ekitan (3646) received approval to change its market segment to the Tokyo Stock Exchange Standard Market. Morpho (3653) announced a buyback of its own shares, with an upper limit of 140,000 shares (2.67% of issued shares), purchased on ToSTNeT-3. The strategic capital and business alliance with Denso (6902) has been dissolved due to the expiration of the technology partnership agreement. Netyear (3622)...

Fisco JapanMar 31 18:30 ET